We are a series A venture-backed biotech company dedicated to treating various inflammatory diseases. We have developed a Novel First-in-Class ARS program (ZMA001 mAb) targeting KARS1 (lysyl-tRNA synthetase) to control inflammation of macrophages with blockbuster potential for the treatment of rare disease in Pulmonary Arterial Hypertension (PAH and PH-ILD) which was derived from our ARSs (aminoacyl-tRNA synthetases) Target Platform Technology (Homeos™). We also have ZMC001 SM (Multi MOA) in candidate stage for the treatment of NASH (excellent efficacy data) as well as highly anticipated H-L stage early oncology program ZMC101 SM (DX2 panKRAS) for colorectal and lung cancer treatments.
As a leading pioneer in the area of ARS centric targets, ZYMEDI is now ready to unlock its innovative and novel therapeutic potential to treat various diseases in inflammation, fibrosis and oncology as our first of many new drug development programs.
As a leading pioneer in the area of ARS centric targets, ZYMEDI is now ready to unlock its innovative and novel therapeutic potential to treat various diseases in inflammation, fibrosis and oncology as our first of many new drug development programs.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2019
Main Therapeutic Focus:
Inflammation
Lead Product in Development:
ZMA001 mAb for Pulmonary Arterial Hypertension
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
